NattoPharma Awarded Grant from Norwegian Research Council

Oslo, Norway (02 July 2020) – The Norwegian Research Council has awarded a grant estimated to be NOK 15 million to NattoPharma ASA (“NattoPharma”) to help fund a multi-year project to develop new vitamin formulations. The project will utilize NattoPharma's MenaQ7® Vitamin K2 as MK -7 and the research part will be conducted together with SINTEF AS, Department of Biotechnology and Nanomedicine (“SINTEF”).

The collaboration between SINTEF and NattoPharma aims to develop new and smart technologies for vitamin formulations, building on NattoPharma’s former successes of developing globally competitive and clinically validated products mixed with SINTEF’s strong background in research within the area of biotechnology and nanomedicine.

“The development of new technologies and the planned innovations in the project will contribute to further development and growth of the national vitamin industry”, says Håvard Sletta, Research manager at the Department of Biotechnology and Nanomedicine at SINTEF.

“We are very excited to receive this grant as it will help us realize a research project that will continue to build on our strong position as market leader in the vitamin K2 world. By executing this project, we expect to take the next step in the development of vitamin formulations and secure our continued leading position in the industry”, says Kjetil Ramsøy, Chief Executive Officer of NattoPharma.


For more information, please contact:

Robert Schrama, CFO


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.


Documents & Links